A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes
NCT00050843
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
220
Enrollment
INDUSTRY
Sponsor class
Conditions
Myelodysplastic Syndromes
Interventions
DRUG:
thalidomide
Sponsor
Celgene Corporation